CN109069589B - 用于心血管病况的司美鲁肽 - Google Patents

用于心血管病况的司美鲁肽 Download PDF

Info

Publication number
CN109069589B
CN109069589B CN201780026303.2A CN201780026303A CN109069589B CN 109069589 B CN109069589 B CN 109069589B CN 201780026303 A CN201780026303 A CN 201780026303A CN 109069589 B CN109069589 B CN 109069589B
Authority
CN
China
Prior art keywords
semaglutide
use according
subject
mace
fatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780026303.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069589A (zh
Inventor
O.K.H.汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109069589(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN109069589A publication Critical patent/CN109069589A/zh
Application granted granted Critical
Publication of CN109069589B publication Critical patent/CN109069589B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
CN201780026303.2A 2016-04-28 2017-04-28 用于心血管病况的司美鲁肽 Active CN109069589B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16167458.5 2016-04-28
EP16188262 2016-09-12
EP16188262.6 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (2)

Publication Number Publication Date
CN109069589A CN109069589A (zh) 2018-12-21
CN109069589B true CN109069589B (zh) 2022-09-06

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780026303.2A Active CN109069589B (zh) 2016-04-28 2017-04-28 用于心血管病况的司美鲁肽

Country Status (24)

Country Link
US (3) US20190134162A1 (enExample)
EP (1) EP3448416B1 (enExample)
JP (1) JP7221694B2 (enExample)
KR (3) KR102778218B1 (enExample)
CN (1) CN109069589B (enExample)
AU (2) AU2017256774B2 (enExample)
BR (1) BR112018072020A2 (enExample)
CA (1) CA3022535A1 (enExample)
CL (1) CL2018003045A1 (enExample)
DK (1) DK3448416T3 (enExample)
ES (1) ES2928007T3 (enExample)
HR (1) HRP20221150T1 (enExample)
HU (1) HUE060040T2 (enExample)
IL (1) IL262390B1 (enExample)
MA (1) MA44762A (enExample)
MX (1) MX2018012700A (enExample)
MY (1) MY202967A (enExample)
PH (1) PH12018502274B1 (enExample)
PL (1) PL3448416T3 (enExample)
RS (1) RS63630B1 (enExample)
RU (1) RU2768283C2 (enExample)
SI (1) SI3448416T1 (enExample)
WO (1) WO2017186896A1 (enExample)
ZA (2) ZA202507395B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102778218B1 (ko) * 2016-04-28 2025-03-10 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
MY206306A (en) * 2018-10-26 2024-12-07 Novo Nordisk As Stable semaglutide compositions and uses thereof
WO2020127950A1 (en) * 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
AU2021208601B2 (en) * 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133082A (zh) * 2005-03-18 2008-02-27 诺和诺德公司 酰化的glp-1化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
KR101819609B1 (ko) * 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
PL3326620T3 (pl) * 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN104039822A (zh) * 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
KR20160075819A (ko) * 2013-11-15 2016-06-29 노보 노르디스크 에이/에스 선택적 pyy 화합물 및 그것의 사용
KR102778218B1 (ko) 2016-04-28 2025-03-10 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133082A (zh) * 2005-03-18 2008-02-27 诺和诺德公司 酰化的glp-1化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Phase 2，Randomized，Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog，Semaglutide，Compared With Placebo and Opeh-Label Liraglutide in Patients With Type 2 Diabetes;Michael A.Nauck等;《Diabetes Care》;20160229;全文 *
Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists;André J Scheen等;《Lancet Diabetes Endocrinol》;20150812;全文 *
Guidance for Industry Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S.Department of Health and Human Services;Food and Drug Administration;《Food and Drug Administration》;20081231;全文 *

Also Published As

Publication number Publication date
US20250262281A1 (en) 2025-08-21
MY202967A (en) 2024-05-31
JP7221694B2 (ja) 2023-02-14
RU2768283C2 (ru) 2022-03-23
PL3448416T3 (pl) 2022-11-07
WO2017186896A1 (en) 2017-11-02
KR20180135012A (ko) 2018-12-19
ZA202507394B (en) 2025-09-25
MA44762A (fr) 2019-03-06
RU2018140900A (ru) 2020-05-28
AU2017256774B2 (en) 2024-07-11
ES2928007T3 (es) 2022-11-14
RU2018140900A3 (enExample) 2020-09-28
HRP20221150T1 (hr) 2022-11-25
EP3448416A1 (en) 2019-03-06
JP2019514925A (ja) 2019-06-06
IL262390A (en) 2018-12-31
AU2017256774A1 (en) 2018-11-01
HUE060040T2 (hu) 2023-01-28
IL262390B1 (en) 2023-05-01
CN109069589A (zh) 2018-12-21
US20190134162A1 (en) 2019-05-09
EP3448416B1 (en) 2022-08-10
ZA202507395B (en) 2025-09-25
KR102778218B1 (ko) 2025-03-10
MX2018012700A (es) 2019-01-30
DK3448416T3 (da) 2022-10-03
CA3022535A1 (en) 2017-11-02
PH12018502274B1 (en) 2024-02-28
US20250288649A1 (en) 2025-09-18
AU2024227113A1 (en) 2024-10-31
PH12018502274A1 (en) 2019-09-09
RS63630B1 (sr) 2022-10-31
CL2018003045A1 (es) 2018-12-14
KR20220147712A (ko) 2022-11-03
KR20250038818A (ko) 2025-03-19
SI3448416T1 (sl) 2022-10-28
BR112018072020A2 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
CN109069589B (zh) 用于心血管病况的司美鲁肽
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
CN110022935A (zh) 用于心血管病况的德谷胰岛素
CN110099719A (zh) 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
CN108883158A (zh) 用于肾脏病况的利拉鲁肽
CN108883159A (zh) 用于糖尿病性足溃疡的利拉鲁肽
HK1261741A1 (en) Semaglutide in cardiovascular conditions
HK1261741B (en) Semaglutide in cardiovascular conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant